These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38257288)

  • 1. Multitasking Pharmacophores Support Cabotegravir-Based Long-Acting HIV Pre-Exposure Prophylaxis (PrEP).
    Wan Z; Shi M; Gong Y; Lucci M; Li J; Zhou J; Yang XL; Lelli M; He X; Mao J
    Molecules; 2024 Jan; 29(2):. PubMed ID: 38257288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.
    Raccagni AR; Galli L; Lucente MF; Candela C; Lolatto R; Trentacapilli B; Ponta G; Messina E; Gianotti N; Castagna A; Nozza S
    AIDS Behav; 2024 Mar; 28(3):907-911. PubMed ID: 37792228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
    Parikh UM; Koss CA; Mellors JW
    Curr HIV/AIDS Rep; 2022 Oct; 19(5):384-393. PubMed ID: 36112336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
    Kovač L; Časar Z
    Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
    [No Abstract]   [Full Text] [Related]  

  • 6. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA
    Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis.
    Prather C; Jeon C
    Am J Health Syst Pharm; 2022 Oct; 79(21):1898-1905. PubMed ID: 35894204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
    Landovitz RJ; Donnell D; Clement ME; Hanscom B; Cottle L; Coelho L; Cabello R; Chariyalertsak S; Dunne EF; Frank I; Gallardo-Cartagena JA; Gaur AH; Gonzales P; Tran HV; Hinojosa JC; Kallas EG; Kelley CF; Losso MH; Madruga JV; Middelkoop K; Phanuphak N; Santos B; Sued O; Valencia Huamaní J; Overton ET; Swaminathan S; Del Rio C; Gulick RM; Richardson P; Sullivan P; Piwowar-Manning E; Marzinke M; Hendrix C; Li M; Wang Z; Marrazzo J; Daar E; Asmelash A; Brown TT; Anderson P; Eshleman SH; Bryan M; Blanchette C; Lucas J; Psaros C; Safren S; Sugarman J; Scott H; Eron JJ; Fields SD; Sista ND; Gomez-Feliciano K; Jennings A; Kofron RM; Holtz TH; Shin K; Rooney JF; Smith KY; Spreen W; Margolis D; Rinehart A; Adeyeye A; Cohen MS; McCauley M; Grinsztejn B;
    N Engl J Med; 2021 Aug; 385(7):595-608. PubMed ID: 34379922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promises and challenges: cabotegravir for preexposure prophylaxis.
    Spinelli MA; Grinsztejn B; Landovitz RJ
    Curr Opin HIV AIDS; 2022 Jul; 17(4):186-191. PubMed ID: 35762372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection.
    Zimmerman H; Vogl A
    Am Fam Physician; 2024 Apr; 109(4):296. PubMed ID: 38648820
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir.
    Han Y; Luo H; Lu Q; Liu Z; Liu J; Zhang J; Wei Z; Li J
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.
    Chen X; Li J; Kou L; Xie X; Wei D; Li Y
    Rev Med Virol; 2023 Jul; 33(4):e2460. PubMed ID: 37198721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.
    El-Haddad A; Erlich D
    Am Fam Physician; 2023 May; 107(5):545-546. PubMed ID: 37192084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV Pre-Exposure Prophylaxis.
    Volpe-Zanutto F; Vora LK; Tekko IA; McKenna PE; Permana AD; Sabri AH; Anjani QK; McCarthy HO; Paredes AJ; Donnelly RF
    J Control Release; 2022 Aug; 348():771-785. PubMed ID: 35738464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.
    Pons-Faudoa FP; Sizovs A; Di Trani N; Paez-Mayorga J; Bruno G; Rhudy J; Manohar M; Gwenden K; Martini C; Chua CYX; Varchi G; Marzinke MA; Grattoni A
    J Control Release; 2019 Jul; 306():89-96. PubMed ID: 31136811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.
    Eshleman SH; Fogel JM; Halvas EK; Piwowar-Manning E; Marzinke MA; Kofron R; Wang Z; Mellors J; McCauley M; Rinehart AR; St Clair M; Adeyeye A; Hinojosa JC; Cabello R; Middelkoop K; Hanscom B; Cohen MS; Grinsztejn B; Landovitz RJ;
    J Infect Dis; 2022 Dec; 226(12):2170-2180. PubMed ID: 36240386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of cabotegravir for HIV treatment and prevention.
    Canetti D; Spagnuolo V
    Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing the Role of Long-Acting Cabotegravir Preexposure Prophylaxis of Human Immunodeficiency Virus: Opportunities and Aspirations.
    Cohen MS; Landovitz RJ
    J Infect Dis; 2021 Jan; 223(1):1-3. PubMed ID: 32882042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.